Resolution of macular oedema associated with retinitis pigmentosa after intravitreal use of autologous BM-derived hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 48, Issue 4, 2013, Pages 612-613

  Siqueira, R C ^a   Messias, A ^a   Voltarelli, J C ^a   Messias, K ^a   Arcieri, R S ^a   Jorge, R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL POPULATION; CELL SUSPENSION; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; HUMAN; LETTER; PARACRINE SIGNALING; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DYSTROPHY; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINITIS PIGMENTOSA; SYSTEMIC DISEASE; THERAPY EFFECT; VISUAL ACUITY; VISUAL IMPAIRMENT;

BONE MARROW CELLS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MACULAR EDEMA; MALE; POSTOPERATIVE COMPLICATIONS; RETINITIS PIGMENTOSA; TRANSPLANTATION, AUTOLOGOUS;

EID: 84876406136     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.185     Document Type: Letter

References (9)

1. Siqueira RC. Stem cell therapy for retinal diseases: update. Stem Cell Res Ther 2011; 2: 50.
2. Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R. Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinaldystro-phy: a phase I trial. Retina 2011; 31: 1207-1214.
3. Siqueira RC. Autologous Bone Marrow-Derived Stem Cells Transplantation for Retinitis Pigmentosa (RETICELL). Clinicaltrial identifier:NCT01560715 [Internet]. Bethesda (MD): National Library of Medicine, 2012, Available from: http://clinicaltrials.gov/ct2/show/NCT01560715?term\NCT01560715&rank\1 (cited 15 April 2012).
4. Ikeda Y, Hisatomi T, Yoshida N, Notomi S, Murakami Y, Enaida H et al. The clinical efficacy of a topical dorzolamide in the management of cystoids macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2012; 250: 809-814.
5. Thobani A, Fishman GA. The use of carbonic anhydrase inhibitors in the retreat-ment of cystic macular lesions in retinitis pigmentosa and X-linked retinoschisis. Retina 2011; 31: 312-315.
6. Moldow B, Sander B, Larsen M, Engler C, Li B, Rosenberg T et al. The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol 1998; 236: 881-889.
7. Vinores SA, Küchle M, Derevjanik NL, Henderer JD, Mahlow J, Green WR et al. Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization. Histol Histopathol 1995; 10: 913-923.
8. Siqueira RC, Voltarelli JC, Messias AM, Jorge R. Possible mechanisms of retinal function recovery with the use of cell therapy with bone marrow-derived stem cells. Arq Bras Oftalmol 2010; 73: 474-479.
9. Tibbetts MD, Samuel MA, Chang TS, Ho AC. Stem cell therapy for retinal disease. Curr Opin Ophthalmol 2012; 23: 226-234.